Evidence map›Paper›PMID 38397990›Full record

ArticleBiomedicines2024

Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?

Valentina Magri, Luca Marino, Gianluigi De Renzi, Michela De Meo, Francesca Salvatori, Dorelsa Buccilli, Vincenzo Bianco, Daniele Santini, Chiara Nicolazzo, Paola Gazzaniga

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Valentina MagriDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-7312-2904
Luca MarinoDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-7380-6222
Gianluigi De RenziDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Michela De MeoDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-3024-2233
Francesca SalvatoriDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.
Dorelsa BuccilliDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.
Vincenzo BiancoDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.
Daniele SantiniDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, Italy.
Chiara NicolazzoDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2551-8979
Paola GazzanigaDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2325-2273
Sapienza University of Rome · IT

Funding

Sapienza University of Rome C26A10ZLW7Sapienza University of Rome C26A12YHEF
6 · The paper itself

Abstract

Early detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, treatment selection mostly relies on criteria based on radiologic evaluations (RECIST). The aim of the present retrospective study is to evaluate the potential inclusion of circulating tumor cells (CTCs) in hybrid criteria. CTC counts from a total of 160 patients with different metastatic tumors were analyzed for this purpose. In our cohort, 73 patients were affected by breast cancer, 69 by colorectal cancer and 18 by prostate cancer. PFS and OS were evaluated according to the corresponding prediction of disease progression by CTCs and RECIST criteria. In breast cancer, CTC-I has an important impact on the progression-free survival (PFS) and overall survival (OS) values. When CTC-I predicted earlier than RECIST-I, the disease progression, the PFS and OS were shorter with respect to the opposite case. In particular, PFS was 11 (5-16) vs. 34 (23-45)-with

Indexed as

circulating tumor cellsdisease progressionmetastatic cancerspersonalized oncologyRECIST criteria

Identifiers

PMID38397990
PMCPMC10887063
OpenAlexW4391599769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.